Stemcell United Osake

Stemcell United EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Stemcell United (SCU.AX) 9.9.2026 päivämäärällä on −2,63 M AUD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −1,84 M AUD — muutos 42,85 % (matalampi).

EBITDA

−2,63 MAUD

YoY

42,85%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Stemcell United on 2026 −2,63 M AUD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Stemcell United oli 2025 −1,84 M AUD. Se laskee 42,85% matalampi edelliseen vuoteen verrattuna.

Stemcell United EBITDA historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

EBITDA
Date
EBITDA
1.1.2015
−1,00 M AUD
1.1.2016
−997 300,00 AUD
1.1.2017
−725 260,00 AUD
1.1.2018
−1,81 M AUD
1.1.2019
−1,52 M AUD
1.1.2020
−1,35 M AUD
1.1.2021
−1,84 M AUD
1.1.2022
−2,63 M AUD
Stemcell United EBITDA historia
VUOSIEBITDAYoY
−2,63 MAUD+42,85%
−1,84 MAUD+36,51%
−1,35 MAUD−11,32%
−1,52 MAUD−15,65%
−1,81 MAUD+148,95%
−725 260,00AUD−27,28%
−997 300,00AUD−0,50%
−1,00 MAUD
Access this data via the Eulerpool API

Stemcell United Osakeanalyysi

Mitä Stemcell United tekee? Stemcell United Ltd is an internationally operating company that is active in the field of stem cell research and therapy. It was founded in 2005 by British entrepreneur and scientist Dr. Samantha Phillips, who previously worked for the renowned Roslin Institute for Animal Genetics. The business model of Stemcell United is based on the development and distribution of innovative therapies that are based on the use of stem cells as a foundation. The company primarily relies on close collaboration with leading research institutions and clinics worldwide to stay up to date with the latest research and develop products and services that are based on current knowledge and meet the highest quality standards. The various divisions of Stemcell United include the development and production of stem cell-based therapies for diseases such as cancer, heart attack, dementia, and stroke. Additionally, the company also offers support and consultation in the field of clinical trials as well as training for doctors and researchers to improve and optimize the use of stem cell therapies. Another important area of Stemcell United's business activities is the production and marketing of stem cells for research purposes. Both embryonic and adult stem cells are produced and provided to advance research in this field and gain new insights. The products offered by Stemcell United mainly include stem cell preparations for wound healing and tissue regeneration, as well as specialized cell cultures for research in the field of stem cell therapy. These products are sold to clinics, research institutions, and end consumers and are available in many countries worldwide. In recent years, Stemcell United has become one of the leading companies in the field of stem cell research and therapy and enjoys a high reputation in the industry. The company primarily relies on close collaboration with other top companies in the industry and a strong connection to research and development in this field. Overall, Stemcell United is an innovative and dynamic company that sets standards in the field of stem cell research and therapy worldwide and constantly seeks new ways to utilize the possibilities of stem cell therapy for the health and well-being of humans and animals. Stemcell United on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Stemcell United osakkeesta

Yhtiön Stemcell United EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −2,63 M AUD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Stemcell United muuttui arvosta −1,84 M AUD arvoon −2,63 M AUD, mikä edustaa 42,85 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Stemcell United:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n AUD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Stemcell United historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Stemcell United

Kaikki tunnusluvut — Stemcell United